Income
2019-2022 cumulative sales revenue
Patient
2019-2022 cumulative patients
Promotion
Subscriptions to the patient education applet
Pipeline
Approved clinical trial application
Our goal is to establish a platform for launching medicines in the Greater China market with CASI’s experienced China-based regulatory and commercial competencies and proficient global drug development expertise.
We have a strong and growing pipeline of commercially available and clinical-staged drug candidates and continue to acquire assets at commercial and/or clinical development stages through in-license and acquisitions.